BRAF and neoplasm: MB231Br and GBM8 are both tumor cell lines that express upregulation or dependency on the MAPK pathway—MB231Br via the BRAF V600E mutation52 and GBM8 via the PTEN deletion53—suggesting sensitivity to the MEK inhibitor trametinib.